NCT07762768

Brief Summary

This is a randomized, controlled, two-phase crossover study will be conducted in adults aged 18-60 years with prediabetes to compare the effects of a CSIR-developed high-protein, low-glycaemic index rice with conventional rice. Phase I will evaluate acute postprandial glucose, insulin, C-peptide, GLP-1, and hunger/satiety responses, while Phase II will assess 72-hour continuous glucose monitoring (CGM) outcomes, including mean glucose and glycaemic variability. Eligible participants will be randomly assigned to receive both rice types in a crossover manner, with each participant serving as their own control. Individuals with diabetes, major systemic illnesses, abnormal liver or renal function, pregnancy, or glucose-lowering medication use will be excluded.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
6mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 5, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 13, 2026

Completed
19 days until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2027

13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2027

Last Updated

August 13, 2026

Status Verified

August 1, 2026

Enrollment Period

6 months

First QC Date

August 5, 2026

Last Update Submit

August 11, 2026

Conditions

Keywords

High-Protein, Low-Glycaemic Index RiceConventional RicePrediabetes

Outcome Measures

Primary Outcomes (1)

  • Study Phase 1: Meal Tolerance Test

    incremental area under the curve(mg/dL)

    1 day

Secondary Outcomes (1)

  • meal tolerance study

    1 day

Study Arms (2)

Intervention Group

ACTIVE COMPARATOR

CSIR-Developed High-Protein, Low-Glycaemic Index Rice

Dietary Supplement: Intervention Group

Control Group

ACTIVE COMPARATOR

Conventional Rice

Dietary Supplement: Intervention Group

Interventions

Intervention GroupDIETARY_SUPPLEMENT

High-Protein, Low-Glycaemic Index Rice

Also known as: CSIR-Developed High-Protein, Low-Glycaemic Index Rice
Control GroupIntervention Group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-60 years
  • Individuals with prediabetes, defined by oral glucose tolerance test (OGTT) as:
  • Fasting plasma glucose ≥100 mg/dL and \<126 mg/dL, and/or
  • hour plasma glucose ≥140 mg/dL and \<200 mg/dL following ingestion of 75 g anhydrous glucose
  • Willingness to participate and comply with study procedures

You may not qualify if:

  • Diagnosed diabetes mellitus
  • Acute infections or any debilitating illness
  • History of hepatic, pancreatic, renal, or cardiovascular disease
  • Abnormal liver or renal function tests
  • Recent (\<3 months) weight change ≥5% or use of weight-altering medications
  • Use of glucose-lowering medications
  • Pregnancy or lactation
  • Known allergy or intolerance to study foods
  • Any condition that, in the investigator's opinion, may interfere with study participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Diabetes, Obesity and Cholesterol Foundation (N-DOC)

New Delhi, National Capital Territory of Delhi, 110016, India

Location

MeSH Terms

Conditions

Prediabetic State

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Anoop Misra, M.D.

    National Diabetes, Obesity and Cholesterol Foundation (N-DOC)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Anoop Misra, M.D.

CONTACT

Seema Gulati, Ph.d

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 5, 2026

First Posted

August 13, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

February 15, 2027

Study Completion (Estimated)

February 28, 2027

Last Updated

August 13, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations